VIVO Earnings & Financial Statements
Meridian Bioscience, Inc.
$2.40
-$0.21(-7.88%)
31
Overall
--
Value
36
Tech
26
Quality
Market Cap
$83.18M
Volume
218.12K
52W Range
$1.20 - $6.86
Target Price
$10.00
VIVO earnings and financial statements: Meridian Bioscience, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VIVO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $61.0K | $16.0K | $4.05M | $20.57M | $23.98M |
| Cost of revenue | $50.0K | $27.0K | $8.14M | -$20.31M | -$19.61M |
| Operating income | -$8.74M | -$8.66M | -$11.74M | -$23.29M | -$6.74M |
| EBITDA | -$7.58M | -$36.68M | -$11.09M | -$20.97M | -$11.12M |
| Net income | -$12.79M | -$43.55M | -$24.36M | -$42.09M | -$14.31M |
| EPS (diluted) | $-1.92 | $-15.17 | $-9.87 | $-1.04 | $-0.49 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $97.13M | $37.43M | $61.42M | $69.66M | $76.51M |
| Total liabilities | $77.02M | $77.97M | $57.67M | $47.69M | $36.09M |
| Shareholders’ equity | $20.10M | -$40.54M | $3.75M | $21.97M | $40.42M |
| Cash and equivalents | $60.0K | $199.0K | $553.0K | $1.28M | $8.60M |
| Long-term debt | $16.94M | $20.91M | $30.00M | $23.45M | $22.09M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.75M | $1.49M | -$5.44M | -$5.13M | -$15.38M |
| Capital expenditure | - | - | - | -$1.11M | -$901.0K |
| Free cash flow | -$6.73M | $884.0K | -$6.36M | -$6.24M | -$16.28M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VIVO | $2.40 | -7.9% | 218.12K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Meridian Bioscience, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW